Humacyte, Inc. (HUMA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Humacyte, Inc. is a commercial-stage biotechnology company developing bioengineered human tissues. The company recently commenced the U.S. commercial launch of its first FDA-approved product, Symvess (acellular tissue engineered vessel), approved in December 2024 for urgent arterial repair in extremity vascular trauma. The company operates as a single reportable segment and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $301 | $818 | $0 |
| Net Income (Loss) | $(37,658) | $1,481 | $(88,559) |
| Operating Loss | $(29,727) | $(52,911) | $(56,077) |
| Net Cash Used in Operating Activities | N/A | $(55,014) | $(48,638) |
| Cash and Cash Equivalents | $38,032 | $38,032 | $44,937 |
| Restricted Cash | $50,209 | $50,209 | $50,209 |
| Working Capital | $30,645 | $30,645 | $27,905 |
| Revenue Interest Liability | $68,541 | $68,541 | $64,239 |
Note: Revenue consists of $100k product revenue and $201k contract revenue for Q2 2025. The YTD 2025 net income of $1.5 million is primarily driven by a non-cash gain of $44.3 million from the remeasurement of the Contingent Earnout Liability.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded its first commercial product revenue ($100k in Q2, $247k YTD) following the March 2025 commercial launch of Symvess, compared to zero revenue in the prior year periods.
- Inventory Capitalization: In early 2025, the company began capitalizing manufacturing costs as inventory ($11.1 million as of June 30, 2025) rather than expensing them as R&D, due to the probability of commercialization. This reduced YTD R&D expenses by approximately $6.0 million compared to the prior year.
- Non-Cash Gains: A significant non-cash gain of $44.3 million (YTD) resulted from the decrease in the fair value of the Contingent Earnout Liability, turning a YTD operating loss into a net income position.
- Cost Reductions: In April 2025, the company implemented a workforce reduction of 30 employees, incurring $0.7 million in severance costs, to extend its cash runway.
- Equity Financing: The company raised approximately $46.7 million in net proceeds from a public offering in March 2025 and utilized its ATM facility for an additional $3.6 million YTD.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash and cash equivalents ($38.0 million) combined with the remaining capacity under the Common Stock Purchase Agreement ($47.5 million) will fund operations for at least 12 months from the filing date.
- Commercialization: The company is focused on the U.S. market launch of Symvess. In July 2025, the Centers for Medicare and Medicaid Services (CMS) declined the company's New Technology Add-On Payment (NTAP) application, though management believes the impact is limited as Medicare covers only ~4.3% of the target vascular trauma population.
- Future Funding: Long-term viability depends on generating cash flows from Symvess sales and raising additional capital. The company plans to seek funding through equity, debt, or strategic collaborations.
- Legal Proceedings: The company is facing a putative securities class action lawsuit (Cutshall v. Humacyte) alleging false statements regarding Symvess safety and manufacturing deficiencies. Several related stockholder derivative actions have been filed but are currently stayed pending the resolution of the securities litigation. The company disputes these claims and has not accrued a liability as the outcome is not estimable.
- Regulatory Pipeline: The company plans to submit a supplemental BLA for Symvess for AV access in hemodialysis in the second half of 2026, dependent on interim results from the V012 Phase 3 trial.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of Symvess product sales and the impact of the CMS NTAP denial on reimbursement and adoption rates.
- Cash Runway: Confirm the sufficiency of the $38 million cash balance and the $47.5 million equity line availability against the projected $55 million annualized operating cash burn.
- Legal Exposure: Monitor the status of the Cutshall securities litigation and the stayed derivative actions for potential material financial impact.
- Inventory Valuation: Assess the risk of inventory write-downs if Symvess market acceptance does not meet expectations before the product shelf-life expires.
- Debt Obligations: Review the terms of the Revenue Interest Purchase Agreement, specifically the 7.5% royalty rate and the potential for increased rates if cumulative payments are not met by the 2028 test date.